Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.
The past few years have been a roller coaster ride for M&A in pharma and biotech. After the highs of the pandemic came ...
Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback